Runway Growth Capital Provides $35MM Long-Term Debt Facility to TRACON Pharmaceuticals
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company, entered into a $35 million non-dilutive long-term debt facility with Runway Growth Capital.
September 7, 2022
Charles Theuer | Igor DaCruz | Runway Growth Capital | TRACON Pharmaceuticals
Ian Koplin